Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK health agency merger

This article was originally published in The Tan Sheet

Executive Summary

Medicines Control Agency, Medical Devices Agency will merge into single, as-yet-unnamed entity next April due to increasing convergence in drug, medical device fields, Department of Health announces June 13. Systems and processes by which drugs are licensed, medical devices are controlled will not be affected, but merger will include creation of chairman post to serve as agency's authoritative figurehead and oversee strategic management. Agency also will have a chief executive; current MCA Chief Exec Keith Jones, MD, is leaving his post in October...

You may also be interested in...

UK health agency

Medicines & Healthcare Products Regulatory Agency will become official April 1 with new Web site at MHRA will consist of Medicines Control Agency and Medical Devices Agency; merger was initiated in June 2002 to address convergence of drug, medical device fields (1"The Tan Sheet" June 17, 2002, In Brief)...

UK medicines agency head

Alasdair Breckenridge, chairman of the Medicines Control Agency's Committee on the Safety of Medicines, named chair-designate of UK's Medicines & Healthcare Products Regulatory Agency, Department of Health announces Nov. 28. MHRA will consist of MCA and Medical Devices Agency and will become official in April 2003 (1"The Tan Sheet" June 17, 2002, In Brief). One of Breckenridge's first responsibilities will be to help appoint a chief exec of MHRA; last day to submit applications for the post was Nov. 20...

Patient-Focused Drug Development, Complex Trial Design Likely Won’t Get More Funding In PDUFA VII

US FDA proposed increasing staffing and resources for both programs during the next user fee program cycle, but industry representatives did not believe it necessary.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts